Eli Casdin
Eli Casdin's purchase track record
How the stock did after each of Eli Casdin's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/17/2023 | LAB | $2.63M | +46.2% | +12.8% | +8.3% |
| 1/31/2023 | WGS | $30.00M | -42.1% | -45.7% | +12.3% |
| 11/17/2022 | TNYA | $6.48M | +9.2% | +188.8% | +6.4% |
| 4/29/2022 | WGS | $45.75M | -24.6% | -51.4% | -5.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Tenaya Therapeutics noted among health‑care stocks moving intraday. Tenaya Therapeutics was listed among twelve health‑care stocks that showed notable intraday movement on Wednesday, according to Benzinga. The activity reflects broader sector momentum and comes while the stock is in oversold territory (RSI 19.6) and near its $0.68 support level.
Transaction History
| LAB | ▲ Buy | Grant | 99,116 | $0 | 6/18/2026 | View on chart |
| WGS | ▲ Buy | Option Exercise | 3,576 | $0 | 6/18/2026 | View on chart |
| LAB | ▲ Buy | Grant | 52,991 | $62K | 2/26/2026 | View on chart |
| LAB | ▲ Buy | Grant | 94,592 | $0 | 6/20/2025 | View on chart |
| WGS | ▲ Buy | Option Exercise | 12,924 | $0 | 6/18/2025 | View on chart |
| LAB | ▲ Buy | Grant | 1,588 | $0 | 7/19/2024 | View on chart |
| LAB | ▲ Buy | Grant | 43,128 | $0 | 6/28/2024 | View on chart |
| WGS | ▲ Buy | Option Exercise | 5,828 | $0 | 6/20/2024 | View on chart |
| LAB | ▲ Buy | Grant | 22,800 | $57K | 2/20/2024 | View on chart |
| LAB | ▲ Buy | Grant | 7,548,000 | — | 1/5/2024 | View on chart |
| LAB | ▲ Buy | Grant | 3,807 | — | 1/5/2024 | View on chart |
| LAB | ▲ Buy | Grant | 3,807 | — | 1/5/2024 | View on chart |
| LAB | ▲ Buy | Grant | 2,744,219 | — | 1/5/2024 | View on chart |
| LAB | ▲ Buy | Grant | 11,246,525 | — | 1/5/2024 | View on chart |
| LAB | ▲ Buy | Grant | 26,376 | $0 | 6/14/2023 | View on chart |
| LAB | ▲ Buy | Open Market | 800,000 | $1.8M | 5/19/2023 | View on chart |
| LAB | ▲ Buy | Open Market | 150,000 | $324K | 5/18/2023 | View on chart |
| LAB | ▲ Buy | Open Market | 250,000 | $472K | 5/17/2023 | View on chart |
| WGS | ▲ Buy | Option Exercise | 45,454 | $0 | 5/2/2023 | View on chart |
| WGS | ▲ Buy | Open Market | 71,428,542 | $25.0M | 1/31/2023 | View on chart |
| WGS | ▲ Buy | Open Market | 14,285,743 | $5.0M | 1/31/2023 | View on chart |
| TNYA | ▲ Buy | Open Market | 2,492,042 | $6.5M | 11/17/2022 | View on chart |
| LAB | ▲ Buy | Grant | 30,914 | $0 | 6/15/2022 | View on chart |
| WGS | ▲ Buy | Open Market | 11,437,500 | $45.8M | 4/29/2022 | View on chart |
| WGS | ▲ Buy | Option Exercise | 12,836 | — | 4/27/2022 | View on chart |
| LAB | ▲ Buy | Grant | 15,852 | $0 | 4/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
GeneDx Shares New Genomic Newborn Screening Data
GeneDx presented new evidence for its genomic newborn screening program at the ICoNS 2026 conference. This update highlights the company's ongoing development in clinical genomics. The stock is currently trading near its 52-week low, with an average analyst target of $93.50.
GeneDx Shares New Genomic Newborn Screening Data. GeneDx presented new evidence for its genomic newborn screening program at the ICoNS 2026 conference. This update highlights the company's ongoing development in clinical genomics. The stock is currently trading near its 52-week low, with an average analyst target of $93.50.